NCT02577458View on ClinicalTrials.gov

Study of the Combination of CM082 With Everolimus in Patients With mRCC

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions
Renal Cell Carcinoma Recurrent
Interventions
DRUG

CM082

CM082 tablets taken orally once a day on 28-day cycles

DRUG

Everolimus

Everolimus tablets taken orally once a day on 28-day cycles

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

AnewPharma
All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

AnewPharma

INDUSTRY

NCT02577458 - Study of the Combination of CM082 With Everolimus in Patients With mRCC | Biotech Hunter | Biotech Hunter